The goal of drug therapy for type 2 diabetes is to achieve and
maintain a near-normal A1C concentration without
inducing hypoglycemia; the target is generally an A1C
of 10,000 patients with type 2 diabetes,
with or at high-risk for cardiovascular disease, found
that treating patients intensively with antihyperglycemic
drugs to an A1C target of 6.0% for a mean of 3.7 years
did not significantly reduce the incidence of major
cardiovascular events (the primary endpoint) and was
associated with increased all-cause mortality compared
to patients treated to an A1C target of 7.0-7.9%. An
A1C target of 7-8% may be prudent in older patients
and in those with underlying cardiovascular disease,
severe hypoglycemia, or multiple diabetes-related
complications
... more